KRAS and neoplasm: An impact of the KRAS mutation was confirmed in this patient's tumor tissue by immunohistochemistry-based morphoproteomics which demonstrated that the Ras/Raf kinase/extracellular signal-regulated kinase (ERK) pathway was constitutively activated with chromogenic signal observed, up to 3+ in nucleus and ± in the cytoplasm, for p-ERK 1/2 (Thr 202/Tyr 204) (Figure 3).